STRATEGY STUDIO / NONPROFIT PEOPLE SEARCH

TRANSCELERATE BIOPHARMA INC: Form 990, tax year 2018

View the entire original 990 at ProPublica ↗

Organization
TRANSCELERATE BIOPHARMA INC (EIN 46-0886344)
Tax period
2018-01-01 to 2018-12-31
Filed
2019-05-13
IRS object ID
201901339349300230
Schema version
2018v3.1
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2019-05-13T09:23:20-05:00ReturnTs
Tax Period End2018-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN131639826PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1EISNERAMPER LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1130 NORTH 18TH STREET SUITE 3000AddressLine1Txt
CityPHILADELPHIACityNm
State AbbreviationPAStateAbbreviationCd
ZIP191032757ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2018-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN460886344EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1TRANSCELERATE BIOPHARMA INCBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlTRANBusinessNameControlTxt
Phone4845391230PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1100 FOUR FALLS CORP CENTER NO 655AddressLine1Txt
CityWEST CONSHOHOCKENCityNm
State AbbreviationPAStateAbbreviationCd
ZIP19428ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonDALVIR GILL PHDPersonNm
Person TitleCEOPersonTitleTxt
Phone4845391230PhoneNum
Signature2019-05-10SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonHELEN M MARTINPreparerPersonNm
PTINP01330899PTIN
Phone2158818800PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

FieldValueIRS element (for citing)
I Pv4 Address64.238.150.4IPv4AddressTxt
FieldValueIRS element (for citing)
IP2019-05-10IPDt
IP Tm09:33:08IPTm
IP TimezoneEDIPTimezoneCd
Filing License TypePFilingLicenseTypeCd
At Submission Creation Device IdDA39A3EE5E6B4B0D3255BFEF95601890AFD80709AtSubmissionCreationDeviceId
At Submission Filing Device Id0EDE4F5BE59FB99924CAAEE7408372872BC47088AtSubmissionFilingDeviceId
FieldValueIRS element (for citing)
Tax2018TaxYr
Build TS2019-02-21 02:37:17ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerDALVIR GILL PHDPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line1100 FOUR FALLS CORP CENTER NO 655AddressLine1Txt
CityWEST CONSHOHOCKENCityNm
State AbbreviationPAStateAbbreviationCd
ZIP19428ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$25,318,445GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501cYes (X)Organization501cInd
Website AddressWWW.TRANSCELERATEBIOPHARMAINC.COMWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2012FormationYr
Legal Domicile StateDELegalDomicileStateCd
Activity Or MissionIMPROVE THE HEALTH OF PEOPLE IN THE WORLD BY ENHANCING THE R&D OF INNOVATIVE THERAPIES.TRANSCELERATE BIOPHARMA INC. IS A NON-PROFIT ORGANIZATION DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES. THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS.ActivityOrMissionDesc
Voting Members Governing Body19VotingMembersGoverningBodyCnt
Voting Members Independent18VotingMembersIndependentCnt
Total Employee14TotalEmployeeCnt
Total Volunteers0TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$0PYContributionsGrantsAmt
CY Contributions Grants$0CYContributionsGrantsAmt
PY Program Service Revenue$26,133,333PYProgramServiceRevenueAmt
CY Program Service Revenue$25,100,000CYProgramServiceRevenueAmt
PY Investment Income$39,247PYInvestmentIncomeAmt
CY Investment Income$218,445CYInvestmentIncomeAmt
PY Other Revenue$0PYOtherRevenueAmt
CY Other Revenue$0CYOtherRevenueAmt
PY Total Revenue$26,172,580PYTotalRevenueAmt
CY Total Revenue$25,318,445CYTotalRevenueAmt
PY Grants And Similar Paid$0PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$0CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$4,790,088PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$4,997,839CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$0CYTotalFundraisingExpenseAmt
PY Other Expenses$24,485,225PYOtherExpensesAmt
CY Other Expenses$25,893,198CYOtherExpensesAmt
PY Total Expenses$29,275,313PYTotalExpensesAmt
CY Total Expenses$30,891,037CYTotalExpensesAmt
PY Revenues Less Expenses-$3,102,733PYRevenuesLessExpensesAmt
CY Revenues Less Expenses-$5,572,592CYRevenuesLessExpensesAmt
Total Assets BOY$43,979,845TotalAssetsBOYAmt
Total Assets EOY$38,632,750TotalAssetsEOYAmt
Total Liabilities BOY$30,831,873TotalLiabilitiesBOYAmt
Total Liabilities EOY$31,059,509TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$13,147,972NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$7,573,241NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTRANSCELERATE BIOPHARMA INC. IS DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES.THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES. TRANSCELERATE EVOLVED FROM CONVERSATIONS AT VARIOUS FORUMS FOR EXECUTIVE R&D LEADERSHIP TO DISCUSS CURRENT ISSUES FACING THE INDUSTRY, AND EXAMINE SOLUTIONS FOR ADDRESSING COMMON CHALLENGES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$23,969,483ExpenseAmt
Revenue$25,100,000RevenueAmt
DescTHE CLINICAL DATA STANDARDS INITIATIVE DELIVERED TWO FINAL PAPERS; ONE ON STANDARDS MAINTENANCE AND VERSIONING AND ANOTHER ON CONSIDERATIONS FOR INTEGRATING STUDY DATA TABULATION MODEL (SDTM). THE CLINICAL RESEARCH ACCESS & INFORMATION EXCHANGE INITIATIVE RELEASED NEW PATIENT-FACING COMMUNICATION TEMPLATES. IN ADDITION, THEIR REGISTRY OF THE FUTURE ("ROTF") PROTOTYPE RECEIVED STRONG SUPPORT FROM MULTIPLE STAKEHOLDER GROUPS.THE CLINICAL RESEARCH AWARENESS INITIATIVE LAUNCHED THE ONE PERSON CLOSER CAMPAIGN TO RAISE AWARENESS ABOUT CLINICAL RESEARCH. THE CAMPAIGN SURPASSED EXPECTATIONS AND ACTIVATED THE GLOBAL HEALTH CARE PRACTITIONER AUDIENCE. THE COMMON PROTOCOL TEMPLATE (CPT) INITIATIVE DELIVERED RELEASE OF VERSION 5 WHICH INCLUDED NEW TA LIBRARIES, TECHNOLOGY ENHANCEMENTS AND PROTOCOL DISCLOSURE ELEMENTS; RELEASE OF VERSION 6 WHICH INCLUDES UPDATE TO CORE CONTENT, NEW LIBRARIES AND TECHNOLOGY ADVANCES; THE CPT WAS TRANSLATED INTO JAPANESE AND SOCIALIZED WITH THE PMDA AND JPMA. THE DATA MONITORING COMMITTEE INITIATIVE HAS DEVELOPED A DMC REGISTRY PROTOTYPE AND APPRENTICESHIP FRAMEWORK. THE DATACELERATE PLATFORM WENT LIVE IN MAY, WITH DATA FROM BIOCELERATE'S TOXICOLOGY DATA SHARING INITIATIVE, AND BACKGROUND CONTROL DATA WAS ADDED IN AUGUST.THE DIGITAL DATA FLOW INITIATIVE DEFINED THEIR YEAR 1 CHARTER AND OBJECTIVES WHICH INCLUDES A WORKING PARTNERSHIP WITH CDISC. THE ELABELS INITIATIVE PUBLISHED THEIR PAPER, THE NEAR-TERM VIABILITY AND BENEFITS OF ELABELS FOR PATIENTS, CLINICAL SITES AND SPONSORS IN DIA TIRS.THE INTERPRETATION OF PV REGULATIONS INITIATIVE DELIVERED A PERSPECTIVE ON FDA IND SAFETY REPORTING REGS AND PUBLICATION OF FINDINGS/CONCLUSIONS; DRAFT PAPER REGARDING REFERENCE SAFETY INFORMATION GUIDANCE AND PUBLICATION OF FINDINGS/CONCLUSIONS; IMPLEMENTATION GUIDE TO AIDE PHARMACEUTICAL MANUFACTURERS UNDERSTANDING OF FDA'S POSTMARKETING SAFETY REPORTING FOR COMBINATION PRODUCTS DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF MARCH 2018; IDENTIFIED COUNTRY LEVEL SIGNAL NOTIFICATION REQUIREMENTS AS THE NEXT REGULATION TO INTERPRET; PUBLISHED "GLOBAL PHARMACOVIGILANCE REGULATIONS: CALL FOR RE-HARMONIZATION" IN CLINICAL TRIALS. THE INVESTIGATOR REGISTRY INITIATIVE COMPLETED THEIR FINAL CORE PRODUCT REQUIREMENT RELEASE TO COMPLETE THE ORIGINAL INITIATIVE OBJECTIVES WITH 13 COMPANIES ADOPTING THE SOLUTION.THE PATIENT EXPERIENCE INITIATIVE PREPARED DRAFTS OF THE PATIENT PROTOCOL ENGAGEMENT TOOLKIT (P-PET) AND THE STUDY PARTICIPANT FEEDBACK QUESTIONNAIRE (SPFQ).THE PATIENT TECHNOLOGY INITIATIVE LAUNCHED THE SHARED INSIGHTS DATABASE WITH 13 COMPANIES SHARING BLINDED DATA RELATED TO THEIR EXPERIENCES IMPLEMENTING VARIOUS PATIENT TECHNOLOGIES. THE PLACEBO STANDARD OF CARE (PSOC) INITIATIVE EXPERIENCED GROWTH IN ADOPTION OF THE SOLUTION WITH 17 COMPANIES PARTICIPATING IN PSOC, AND PUBLISHED A MANUSCRIPT MINIMIZING PATIENT BURDEN THROUGH THE USE OF HISTORICAL SUBJECT-LEVEL DATA IN INNOVATIVE CONFIRMATORY CLINICAL TRIALS.THE PROTOCOL DEVIATION IS CURRENTLY ENGAGING WITH THE FDA AND WORKING ON DEVELOPING A FRAMEWORK AND TOOLKIT FOR IDENTIFYING AND REPORTING PROTOCOL DEVIATIONS.THE SHARED INVESTIGATOR PLATFORM INITIATIVE DELIVERED RELEASE 2.1 AND 2.2 (CRITICAL FUNCTIONALITY ALONG WITH DOCUMENT EXCHANGE AND SAFETY NOTIFICATIONS) FOR THE SHARED INVESTIGATOR PLATFORM ("SIP"); RELEASE 3.0 (CAPABILITY TO MIGRATE ALL ONGOING STUDIES AND ALLOWS FOR MASS ONBOARDING); COMPLETED THE SIP IMPLEMENTATION GUIDE TO SUPPORT ADOPTION AND THE SIP CRO PLAYBOOK TO SUPPORT THE ONBOARDING OF CRO PARTNERS.THE SITE QUALIFICATION & TRAINING INITIATIVE RELEASED NEW VERSIONS OF SEVERAL KEY FORMS AND DOCUMENTS TO BE MORE ACCESSIBLE TO INVESTIGATORS AND SITE STAFF AND MORE CLOSELY ALIGNED WITH THE CONTENT AVAILABLE ON THE SIP.THE VALUE OF SAFETY INFORMATION DATA SOURCES INITIATIVE SHARED KEY INSIGHTS WITH THE FDA, EMA, AND PMDA, IN RESPONSE TO WHICH THE EMA EXPRESSED STRONG INTEREST IN ADDRESSING THE CHALLENGE OF THE RAPIDLY INCREASING VOLUME OF ADVERSE EVENT REPORTING AT AN INTERNATIONAL AND MULTI-REGIONAL SCALE. THE TEAM PREPARED TWO PUBLICATIONS BASED ON THEIR EVIDENCE.Desc
Total Program Service Expenses$23,969,483TotalProgramServiceExpensesAmt
Described In Section501c30DescribedInSection501c3Ind
Schedule B Required0ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Subject To Proxy TaxYes (1)SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Temp Or Permanent Endowments0TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other Liabilities0ReportOtherLiabilitiesInd
Include FIN48 Footnote0IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt0IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign Activities0ForeignActivitiesInd
More Than5000 K To Org0MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising Activities0FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To Organizations0GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With Officer Ent0BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri0DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded EntityYes (1)DisregardedEntityInd
Related Entity0RelatedEntityInd
Related Organization Ctrl Ent0RelatedOrganizationCtrlEntInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document36IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (1)BackupWthldComplianceInd
Employee14EmployeeCnt
Employment Tax Returns FiledYes (1)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht PymtYes (1)SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members19GoverningBodyVotingMembersCnt
Independent Voting Member18IndependentVotingMemberCnt
Family Or Business Rln0FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or StockholdersYes (1)MembersOrStockholdersInd
Election Of Board MembersYes (1)ElectionOfBoardMembersInd
Decisions Subject To Approva0DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn BodyYes (1)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (1)WhistleblowerPolicyInd
Document Retention Policy0DocumentRetentionPolicyInd
Compensation Process CEOYes (1)CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1ANTHONY GARGES HEAD OF FINANCE AND ADMINISTRATIONBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone4845391235PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1100 FOUR FALLS CORP CENTER SUITEAddressLine1Txt
CityWEST CONSHOHOCKENCityNm
State AbbreviationPAStateAbbreviationCd
ZIP19428ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (27 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtOfficerOfficerIndKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
ELLIOTT LEVY
CHAIR OF BOARD OF DIRECTOR0.50Yes (X)$0$0$0
DAVID NICHOLSON
VICE CHAIR OF BOARD OF DIR0.50Yes (X)$0$0$0
JOHN OIDTMAN
BOARD MEMBER0.50Yes (X)$0$0$0
BADHRI SRINIVASAN
BOARD MEMBER0.50Yes (X)$0$0$0
BERNHARDT ZEIHER
BOARD MEMBER0.50Yes (X)$0$0$0
THOR VOIGT
BOARD MEMBER0.50Yes (X)$0$0$0
JOHN REED
BOARD MEMBER0.50Yes (X)$0$0$0
IRIS LOEW-FRIEDRICH
BOARD MEMBER0.50Yes (X)$0$0$0
ROBERT METCALF
BOARD MEMBER0.50Yes (X)$0$0$0
KATHRYN OWEN
BOARD MEMBER0.50Yes (X)$0$0$0
MICHELLE ROHRER
BOARD MEMBER0.50Yes (X)$0$0$0
PAUL STOFFELS
BOARD MEMBER0.50Yes (X)$0$0$0
MARTIN HOLST LANGE
BOARD MEMBER0.50Yes (X)$0$0$0
ROB SCOTT
BOARD MEMBER0.50Yes (X)$0$0$0
ROD MACKENZIE
BOARD MEMBER0.50Yes (X)$0$0$0
ROY BAYNES
BOARD MEMBER0.50Yes (X)$0$0$0
SEAN BOHEN
BOARD MEMBER0.50Yes (X)$0$0$0
TAKUKO YAMADA-SAWADA
BOARD MEMBER0.50Yes (X)$0$0$0
DALVIR GILL
CHIEF EXECUTIVE OFFICER40.00Yes (X)$1,693,688$0$52,371Yes (X)
ULO PALM
CORPORATE SECRETARY0.50$0$0$0Yes (X)
ANDREW LEE
TREASURER0.50$0$0$0Yes (X)
JANICE CHANG
EXECUTIVE VICE PRESIDENT40.00$514,814$0$39,146Yes (X)
JENNIFER A BURGESS
EXECUTIVE DIRECTOR OF COMMUNICATIONS & ENGAGEMENT40.00$316,106$0$39,877Yes (X)
CARA L RINALDI
SENIOR DIRECTOR OF PORTFOLIO MANAGEMENT40.00$241,437$0$36,028Yes (X)
ANTHONY GARGES
HEAD OF FINANCE AND ADMINISTRATION40.00$208,844$0$28,570Yes (X)
JENEEN DONADEO
DIRECTOR, PROGRAM MANAGEMENT40.00$230,824$0$28,849Yes (X)
DENISE REYES
DIRECTOR OF PORTFOLIO MANAGEMENT40.00$207,081$0$11,059Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$3,412,794TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$235,900TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K12IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmtAddress Line1ContractorAddress/ForeignAddress/AddressLine1TxtCityContractorAddress/ForeignAddress/CityNmCountryContractorAddress/ForeignAddress/CountryCd
ACCENTURE LLP
161 N CLARK STREETCHICAGOIL60601CONSULTING & IT SERVICES$7,792,946
COGNIZANT
211 QUALITY CIRCLECOLLEGE STATIONTX77845IT SERVICES$6,484,520
KILPATRICK TOWNSEND
601 14TH STREET NW SUITE 900WASHINGTONDC20005LEGAL SERVICES$2,598,623
PA CONSULTING GROUP INC
IT SERVICES$2,036,69710 BRESSENDEN PLACELONDONUK
SLALOM LLC
821 2ND AVENUE SUITE 1900SEATTLEWA98104CONSULTING & IT SERVICES$934,604
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K23CntrctRcvdGreaterThan100KCnt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescMEMBERSHIP DUESDesc
Business900099BusinessCd
Total Revenue Column$25,100,000TotalRevenueColumnAmt
Related Or Exempt Func Income$25,100,000RelatedOrExemptFuncIncomeAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$25,100,000TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$218,445TotalRevenueColumnAmt
Exclusion$218,445ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$25,318,445TotalRevenueColumnAmt
Related Or Exempt Func Income$25,100,000RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$218,445ExclusionAmt
FieldValueIRS element (for citing)
Info In Schedule O Part IXYes (X)InfoInScheduleOPartIXInd

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$2,300,019TotalAmt
Management And General$2,300,019ManagementAndGeneralAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$2,180,000TotalAmt
Program Services$1,066,284ProgramServicesAmt
Management And General$1,113,716ManagementAndGeneralAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$63,086TotalAmt
Program Services$20,180ProgramServicesAmt
Management And General$42,906ManagementAndGeneralAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$284,056TotalAmt
Program Services$10,419ProgramServicesAmt
Management And General$273,637ManagementAndGeneralAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$170,678TotalAmt
Program Services$59,789ProgramServicesAmt
Management And General$110,889ManagementAndGeneralAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$2,608,134TotalAmt
Program Services$1,890,955ProgramServicesAmt
Management And General$717,179ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$128,370TotalAmt
Management And General$128,370ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$16,744,422TotalAmt
Program Services$15,858,979ProgramServicesAmt
Management And General$885,443ManagementAndGeneralAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$75,801TotalAmt
Program Services$39,712ProgramServicesAmt
Management And General$36,089ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$170,520TotalAmt
Program Services$1,722ProgramServicesAmt
Management And General$168,798ManagementAndGeneralAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$4,210,696TotalAmt
Program Services$4,028,247ProgramServicesAmt
Management And General$182,449ManagementAndGeneralAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$140,035TotalAmt
Management And General$140,035ManagementAndGeneralAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$525,528TotalAmt
Program Services$263,754ProgramServicesAmt
Management And General$261,774ManagementAndGeneralAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$913,137TotalAmt
Program Services$681,565ProgramServicesAmt
Management And General$231,572ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$513TotalAmt
Management And General$513ManagementAndGeneralAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$138,868TotalAmt
Program Services$240ProgramServicesAmt
Management And General$138,628ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDescTotalTotalAmtManagement And GeneralManagementAndGeneralAmtProgram ServicesProgramServicesAmt
EXCESS COMPENSATION TAX$145,674$145,674
RECRUITING$49,476$2,436$47,040
FACILITIES COSTS$38,034$38,034
DUES$2,283$2,283

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$1,707TotalAmt
Program Services$597ProgramServicesAmt
Management And General$1,110ManagementAndGeneralAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$30,891,037TotalAmt
Program Services$23,969,483ProgramServicesAmt
Management And General$6,921,554ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$2,926,545BOYAmt
EOY$7,611,789EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$12,842,533BOYAmt
EOY$1,000,110EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$23,100,000BOYAmt
EOY$24,620,000EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$101,107BOYAmt
EOY$143,842EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$14,458LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$14,458LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$512BOYAmt
EOY$0EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$4,997,301BOYAmt
EOY$5,245,162EOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$11,847BOYAmt
EOY$11,847EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$43,979,845BOYAmt
EOY$38,632,750EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$5,731,873BOYAmt
EOY$4,759,509EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$25,100,000BOYAmt
EOY$26,300,000EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$30,831,873BOYAmt
EOY$31,059,509EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY$13,147,972BOYAmt
EOY$7,573,241EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$13,147,972BOYAmt
EOY$7,573,241EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$43,979,845BOYAmt
EOY$38,632,750EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss-$5,572,592ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst-$2,139NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets$0OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS Audited0FSAuditedInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
Substantially All Dues Nonded0SubstantiallyAllDuesNondedInd
Only In House LobbyingYes (1)OnlyInHouseLobbyingInd
Agree Carryover Prior Year0AgreeCarryoverPriorYearInd

Schedule D IRS990ScheduleD

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$4,202OtherCostOrOtherBasisAmt
Depreciation$4,202DepreciationAmt
Book Value$0BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$10,256OtherCostOrOtherBasisAmt
Depreciation$10,256DepreciationAmt
Book Value$0BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$0TotalBookValueLandBuildingsAmt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr Plan0SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
DALVIR GILL
CHIEF EXECUTIVE OFFICER$594,311$0$1,099,377$0$0$0$11,000$0$41,371$0$1,746,059$0$0$0
JANICE CHANG
EXECUTIVE VICE PRESIDENT$385,717$0$129,097$0$0$0$11,000$0$28,146$0$553,960$0$0$0
JENNIFER A BURGESS
EXECUTIVE DIRECTOR OF COMMUNICATIONS$253,041$0$63,065$0$0$0$11,000$0$28,877$0$355,983$0$0$0
CARA L RINALDI
SENIOR DIRECTOR OF PORTFOLIO MANAGEM$200,797$0$40,640$0$0$0$0$0$36,028$0$277,465$0$0$0
ANTHONY GARGES
HEAD OF FINANCE AND ADMINISTRATION$161,978$0$46,866$0$0$0$8,400$0$20,170$0$237,414$0$0$0
JENEEN DONADEO
DIRECTOR, PROGRAM MANAGEMENT$200,074$0$30,750$0$0$0$9,290$0$19,559$0$259,673$0$0$0
DENISE REYES
DIRECTOR OF PORTFOLIO MANAGEMENT$160,776$0$46,305$0$0$0$1,245$0$9,814$0$218,140$0$0$0

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 3FormAndLineReferenceDesc
ExplanationTHE BOARD CHAIR, WITH INPUT FROM OTHER DIRECTORS OR A SUBCOMMITTEE OF THE BOARD, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (7 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART VI, SECTION A, LINE 6THE MEMBERS OF THE CORPORATION CONSIST OF SUCH FIRMS AND CORPORATIONS THAT ARE APPROVED FOR MEMBERSHIP FROM TIME TO TIME BY THE BOARD OF DIRECTORS OR ITS DESIGNEES IN ACCORDANCE WITH THE POLICIES AND PROCEDURES OF THE CORPORATION. THE CORPORATION HAS THE FOLLOWING CATEGORIES OF MEMBERS: A. TIER I MEMBERS - TO BE ELIGIBLE FOR TIER I MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT IN EXCESS OF $2.5 BILLION. ELIGIBILITY FOR TIER I MEMBERSHIP IS ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. THE INITIAL TIER I MEMBERS ARE FURTHER DEFINED AS THE "CHARTER MEMBERS." B. TIER II MEMBERS - TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $100 MILLION. ELIGIBILITY FOR TIER II MEMBERSHIP WILL BE ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. C. ASSOCIATE MEMBERS - TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION.
FORM 990, PART VI, SECTION A, LINE 7ATHE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY-ONE (21) MEMBERS; PROVIDED THAT: (I) TEN (10) SEATS ARE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE CHARTER MEMBERS; (II) UP TO THREE (3) ADDITIONAL SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE NOT CHARTER MEMBERS; (III) UP TO SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS; (IV) ONE (1) SEAT SHALL BE FILLED BY A DIRECTOR WHO IS A REPRESENTATIVE OF THE ASSOCIATE MEMBERS; AND (V) ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION. THE CORPORATION'S BYLAWS STATE THAT DIRECTORS SHALL BE ELECTED OR APPOINTED, AS APPLICABLE, ANNUALLY AT THE ANNUAL MEETING OF MEMBERS AND SHALL SERVE UNTIL THE FOLLOWING ANNUAL MEETING OF MEMBERS AND UNTIL THEIR SUCCESSORS ARE ELECTED OR APPOINTED, AS APPLICABLE, AND QUALIFIED. EACH CHARTER MEMBER SHALL HAVE THE RIGHT TO APPOINT A REPRESENTATIVE OF THE CHARTER MEMBER TO SERVE AS A CHARTER MEMBER DIRECTOR. TIER I AT-LARGE DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER I MEMBERS, WHICH INCLUDE THE CHARTER MEMBERS. TIER II DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER II MEMBERS. THE ASSOCIATE MEMBER DIRECTOR SHALL BE ELECTED BY A PLURALITY VOTE OF THE ASSOCIATE MEMBERS. THE CEO DIRECTOR SHALL SERVE EX-OFFICIO, FOR SO LONG AS HE OR SHE SHALL HOLD THE OFFICE OF CHIEF EXECUTIVE OFFICER. TRANSCELERATE DOES NOT PRESENTLY HAVE ANY ASSOICATE MEMBERS THEREFORE, THE ASSOICATE MEMBER BOARD SEAT IS CURRENTLY VACANT. EACH TIER I MEMBER SHALL BE ENTITLED TO THREE (3) VOTES AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER 1 MEMBERS ARE ENTITLED TO VOTE. EACH TIER II MEMBER SHALL BE ENTITLED TO ONE (1) VOTE AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER II MEMBERS ARE ENTITLED TO VOTE. ASSOCIATE MEMBERS SHALL BE ENTITLED TO NOTICE OF AND TO ATTEND MEETINGS OF THE MEMBERS BUT SHALL NOT BE ENTITLED TO VOTE AT SUCH MEETINGS, PROVIDED HOWEVER, ASSOCIATE MEMBERS SHALL HAVE THE RIGHT TO CAST ONE (1) VOTE EACH WITH RESPECT TO THE ELECTION OF THE NOMINEE TO FILL THE ASSOCIATE MEMBER BOARD POSITION. NOTWITHSTANDING THE ABOVE, IN ORDER TO BE ELIGIBLE TO VOTE, A MEMBER MUST BE IN GOOD STANDING AND ITS DUES AND ASSESSMENTS PAID IN FULL.
FORM 990, PART VI, SECTION B, LINE 11BTHE FINANCE COMMITTEE AND MANAGEMENT REVIEW AND APPROVE THE FORM 990. THE FORM IS THEN DISTRIBUTED TO ALL MEMBERS OF THE BOARD FOR THEIR REVIEW BEFORE FILING WITH THE INTERNAL REVENUE SERVICE.
FORM 990, PART VI, SECTION B, LINE 12CEACH DIRECTOR AND OFFICER OF THE CORPORATION IS REQUIRED TO ANNUALLY ACKNOWLEDGE THE CONFLICT OF INTEREST POLICY, AFFIRMING THAT SUCH PERSON HAS RECEIVED, READ AND UNDERSTANDS, AND AGREED TO COMPLY WITH THE CONFLICT OF INTEREST POLICY.
FORM 990, PART VI, SECTION B, LINE 15THE BOARD CHAIR, WITH INPUT FROM OTHER DIRECTORS OR A SUBCOMMITTEE OF THE BOARD, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE. THE CEO APPROVES THE COMPENSATION FOR THE EXECUTIVE VICE PRESIDENT, ALONG WITH ALL OTHER KEY EMPLOYEES.
FORM 990, PART VI, SECTION C, LINE 19THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY AND OTHER CORPORATE POLICIES ARE AVAILABLE UPON REQUEST.
FORM 990, PART IX, LINE 11GEXTERNAL CONTRACTOR SUPPORT: PROGRAM SERVICE EXPENSES 7,634,931. MANAGEMENT AND GENERAL EXPENSES 131,595. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 7,766,526. PROJECT MANAGEMENT FEES: PROGRAM SERVICE EXPENSES 7,853,723. MANAGEMENT AND GENERAL EXPENSES 76,009. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 7,929,732. COMMUNICATIONS FEES: PROGRAM SERVICE EXPENSES 370,325. MANAGEMENT AND GENERAL EXPENSES 677,839. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,048,164.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp

Disregarded Entity Name DisregardedEntityName

FieldValueIRS element (for citing)
Business Name Line1BIOCELERATE LLCBusinessNameLine1Txt

US Address USAddress

FieldValueIRS element (for citing)
Address Line1100 FOUR FALLS CORP CENTER SUITE 65AddressLine1Txt
CityWEST CONSHOHOCKENCityNm
State AbbreviationPAStateAbbreviationCd
ZIP19428ZIPCd
FieldValueIRS element (for citing)
EIN475492971EIN
Primary ActivitiesTO IMPROVE EFFICIENCIES IN PRECLINICAL RESEARCH.PrimaryActivitiesTxt
Legal Domicile StateDELegalDomicileStateCd
Total Income$1,100,000TotalIncomeAmt
End Of Year Assets$1,632,801EndOfYearAssetsAmt

Direct Controlling Entity Name DirectControllingEntityName

FieldValueIRS element (for citing)
Business Name Line1TRANSCELERATE BIOPHARMA INCBusinessNameLine1Txt